SUMMITS EXCIMER PHOTOTHERAPEUTIC KERATECTOMY LASER
This article was originally published in The Gray Sheet
Executive Summary
SUMMITS EXCIMER PHOTOTHERAPEUTIC KERATECTOMY LASER should not be indicated for recurrent erosions, FDA's Ophthalmic Devices Advisory Panel concluded at its March 21 meeting. The panel voted 9-1 in favor of the firm's excimer laser for the treatment of patients with pathologic corneal conditions sufficiently severe to adversely affect visual acuity and/or cause discomfort. The recommendation for approval specifically excluded Summit's "listed indications...for recurrent erosions" after panel members zeroed in on the absence of a control study group.
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.